Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
Add more filters










Publication year range
1.
J Pharmacol Exp Ther ; 367(3): 494-508, 2018 12.
Article in English | MEDLINE | ID: mdl-30305428

ABSTRACT

Monoacylglycerol lipase (MGLL) is the primary degradative enzyme for the endocannabinoid 2-arachidonoylglycerol (2-AG). The first MGLL inhibitors have recently entered clinical development for the treatment of neurologic disorders. To support this clinical path, we report the pharmacological characterization of the highly potent and selective MGLL inhibitor ABD-1970 [1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-chlorobenzyl)piperazine-1-carboxylate]. We used ABD-1970 to confirm the role of MGLL in human systems and to define the relationship between MGLL target engagement, brain 2-AG concentrations, and efficacy. Because MGLL contributes to arachidonic acid metabolism in a subset of rodent tissues, we further used ABD-1970 to evaluate whether selective MGLL inhibition would affect prostanoid production in several human assays known to be sensitive to cyclooxygenase inhibitors. ABD-1970 robustly elevated brain 2-AG content and displayed antinociceptive and antipruritic activity in a battery of rodent models (ED50 values of 1-2 mg/kg). The antinociceptive effects of ABD-1970 were potentiated when combined with analgesic standards of care and occurred without overt cannabimimetic effects. ABD-1970 also blocked 2-AG hydrolysis in human brain tissue and elevated 2-AG content in human blood without affecting stimulated prostanoid production. These findings support the clinical development of MGLL inhibitors as a differentiated mechanism to treat pain and other neurologic disorders.


Subject(s)
Endocannabinoids/metabolism , Enzyme Inhibitors/pharmacology , Monoacylglycerol Lipases/antagonists & inhibitors , Analgesics/pharmacology , Animals , Antipruritics/pharmacology , Arachidonic Acids/metabolism , Brain/drug effects , Brain/metabolism , Cell Line, Tumor , Cyclooxygenase Inhibitors/pharmacology , Glycerides/metabolism , Humans , Hydrolysis/drug effects , Male , Mice , Mice, Inbred ICR , PC-3 Cells , Pain/drug therapy , Pain/metabolism , Piperidines/pharmacology , Prostaglandins/pharmacology , Rats , Rats, Sprague-Dawley , Rodentia
2.
J Med Chem ; 61(20): 9062-9084, 2018 10 25.
Article in English | MEDLINE | ID: mdl-30067909

ABSTRACT

The serine hydrolase monoacylglycerol lipase (MGLL) converts the endogenous cannabinoid receptor agonist 2-arachidonoylglycerol (2-AG) and other monoacylglycerols into fatty acids and glycerol. Genetic or pharmacological inactivation of MGLL leads to elevation in 2-AG in the central nervous system and corresponding reductions in arachidonic acid and eicosanoids, producing antinociceptive, anxiolytic, and antineuroinflammatory effects without inducing the full spectrum of psychoactive effects of direct cannabinoid receptor agonists. Here, we report the optimization of hexafluoroisopropyl carbamate-based irreversible inhibitors of MGLL, culminating in a highly potent, selective, and orally available, CNS-penetrant MGLL inhibitor, 28 (ABX-1431). Activity-based protein profiling experiments verify the exquisite selectivity of 28 for MGLL versus other members of the serine hydrolase class. In vivo, 28 inhibits MGLL activity in rodent brain (ED50 = 0.5-1.4 mg/kg), increases brain 2-AG concentrations, and suppresses pain behavior in the rat formalin pain model. ABX-1431 (28) is currently under evaluation in human clinical trials.


Subject(s)
Drug Discovery , Monoacylglycerol Lipases/antagonists & inhibitors , Nervous System Diseases/drug therapy , Nervous System Diseases/enzymology , Piperazine/pharmacology , Piperazines/pharmacology , Pyrrolidines/pharmacology , Animals , Dogs , Dose-Response Relationship, Drug , Humans , Male , Mice , Molecular Targeted Therapy , Pain/drug therapy , Pain/enzymology , Piperazine/pharmacokinetics , Piperazine/therapeutic use , Piperazines/pharmacokinetics , Piperazines/therapeutic use , Pyrrolidines/pharmacokinetics , Pyrrolidines/therapeutic use , Rats , Tissue Distribution
3.
Am J Physiol Gastrointest Liver Physiol ; 305(7): G483-95, 2013 Oct 01.
Article in English | MEDLINE | ID: mdl-23886860

ABSTRACT

Shortcomings of previously reported preclinical models of nonalcoholic steatohepatitis (NASH) include inadequate methods used to induce disease and assess liver pathology. We have developed a dietary model of NASH displaying features observed clinically and methods for objectively assessing disease progression. Mice fed a diet containing 40% fat (of which ∼18% was trans fat), 22% fructose, and 2% cholesterol developed three stages of nonalcoholic fatty liver disease (steatosis, steatohepatitis with fibrosis, and cirrhosis) as assessed by histological and biochemical methods. Using digital pathology to reconstruct the left lateral and right medial lobes of the liver, we made comparisons between and within lobes to determine the uniformity of collagen deposition, which in turn informed experimental sampling methods for histological, biochemical, and gene expression analyses. Gene expression analyses conducted with animals stratified by disease severity led to the identification of several genes for which expression highly correlated with the histological assessment of fibrosis. Importantly, we have established a biopsy method allowing assessment of disease progression. Mice subjected to liver biopsy recovered well from the procedure compared with sham-operated controls with no apparent effect on liver function. Tissue obtained by biopsy was sufficient for gene and protein expression analyses, providing the opportunity to establish an objective method of assessing liver pathology before subjecting animals to treatment. The improved assessment techniques and the observation that mice fed the high-fat diet exhibit many clinically relevant characteristics of NASH establish a preclinical model for identifying pharmacological interventions with greater likelihood of translating to the clinic.


Subject(s)
Dietary Fats/adverse effects , Fatty Liver/etiology , Fatty Liver/pathology , Animals , Gene Expression Regulation/drug effects , Liver/metabolism , Liver Cirrhosis/etiology , Male , Mice , Mice, Inbred C57BL , Non-alcoholic Fatty Liver Disease , Transcriptome
4.
Eur J Pharmacol ; 698(1-3): 292-8, 2013 Jan 05.
Article in English | MEDLINE | ID: mdl-23178527

ABSTRACT

Antagonism of opioid systems (e.g., with naltrexone) has been explored as an anti-obesity strategy, and is particularly effective when co-administered with dual inhibitors of dopamine and norepinephrine reuptake (e.g., bupropion). Previously, we demonstrated that amylin enhances the food intake lowering and weight loss effects of neurohormonal (e.g., leptin, cholecystokinin, melanocortins) and small molecule (e.g., phentermine, sibutramine) agents. Here, we sought to characterize the interaction of amylin with naltrexone/bupropion on energy balance. Wild-type and amylin knockout mice were similarly responsive to the food intake lowering effects of either naltrexone (1mg/kg, subcutaneous) or bupropion (50mg/kg, subcutaneous) suggesting that they act independently of amylinergic systems and could interact additively when given in combination with amylin. To test this, diet-induced obese rats were treated (for 11 days) with vehicle, rat amylin (50 µg/kg/d, infused subcutaneously), naltrexone/bupropion (1 and 20mg/kg, respectively by twice daily subcutaneous injection) or their combination. We found that amylin+naltrexone/bupropion combination therapy exerted additive effects to reduce cumulative food intake, body weight and fat mass. In a separate study, the effects of amylin and naltrexone/bupropion administered at the same doses (for 14 days) were compared to a pair-fed group. Although the combination and pair-fed groups lost a similar amount of body weight, rats treated with the combination lost 68% more fat and better maintained their lean mass. These findings support the strategy of combined amylin agonism with opioid and catecholaminergic signaling systems for the treatment of obesity.


Subject(s)
Appetite Depressants/pharmacology , Body Weight/drug effects , Bupropion/pharmacology , Eating/drug effects , Islet Amyloid Polypeptide/metabolism , Naltrexone/pharmacology , Animals , Body Composition/drug effects , Diet/adverse effects , Drug Interactions , Gene Expression Regulation/drug effects , Gene Knockout Techniques , Islet Amyloid Polypeptide/deficiency , Islet Amyloid Polypeptide/genetics , Male , Mice , Obesity/etiology , Obesity/metabolism , Obesity/physiopathology , Rats , Time Factors
5.
Cell Metab ; 15(3): 299-310, 2012 Mar 07.
Article in English | MEDLINE | ID: mdl-22405068

ABSTRACT

The endocannabinoid system plays a critical role in the control of energy homeostasis, but the identity and localization of the endocannabinoid signal involved remain unknown. In the present study, we developed transgenic mice that overexpress in forebrain neurons the presynaptic hydrolase, monoacylglycerol lipase (MGL), which deactivates the endocannabinoid 2-arachidonoyl-sn-glycerol (2-AG). MGL-overexpressing mice show a 50% decrease in forebrain 2-AG levels but no overt compensation in other endocannabinoid components. This biochemical abnormality is accompanied by a series of metabolic changes that include leanness, elevated energy cost of activity, and hypersensitivity to ß(3)-adrenergic-stimulated thermogenesis, which is corrected by reinstating 2-AG activity at CB(1)-cannabinoid receptors. Additionally, the mutant mice are resistant to diet-induced obesity and express high levels of thermogenic proteins, such as uncoupling protein 1, in their brown adipose tissue. The results suggest that 2-AG signaling through CB(1) regulates the activity of forebrain neural circuits involved in the control of energy dissipation.


Subject(s)
Arachidonic Acids/metabolism , Energy Metabolism/physiology , Glycerides/metabolism , Prosencephalon/metabolism , Signal Transduction/physiology , Animals , Endocannabinoids , Energy Metabolism/genetics , Hypothalamus/metabolism , Immunohistochemistry , Mice , Mice, Transgenic , Monoacylglycerol Lipases/genetics , Monoacylglycerol Lipases/metabolism , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Signal Transduction/genetics
6.
Eur J Med Chem ; 46(9): 4466-73, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21820769

ABSTRACT

Secondary alkylcarbamic acid biphenyl-3-yl esters are a class of Fatty Acid Amide Hydrolase (FAAH) inhibitors, which include the reference compounds URB597 and URB694. Given the intrinsic reactivity of the carbamate group, the in vivo potency of these molecules in rats is strongly affected by their hydrolysis in plasma or hepatic metabolism. In the present study, in vitro chemical and metabolic stability assays (rat plasma and rat liver S(9) fraction) were used to investigate the structure-property relationships (SPRs) for a focused series of title compounds, where lipophilicity and steric hindrance of the carbamate N-substituent had been modulated. The resulting degradation rates indicate that a secondary or tertiary alkyl group at the carbamate nitrogen atom increases hydrolytic stability towards rat plasma esterases. The calculated solvent accessible surface area (SASA) of the carbamate fragment was employed to describe the differences observed in rate constants of hydrolysis in rat plasma (log k(plasma)), suggesting that stability in plasma increases if the substituent exerts a shielding effect on the carbamate carbonyl. Stability in rat liver S(9) fraction is increased when a tertiary carbon is bound to the carbamate nitrogen atom, while other steric effects showed complex relationships with degradation rates. The SPRs here described may be applied at the pharmacokinetic optimization of other classes of carbamate FAAH inhibitors.


Subject(s)
Amidohydrolases/antagonists & inhibitors , Blood , Carbamates/pharmacology , Enzyme Inhibitors/pharmacology , Liver/drug effects , Animals , Area Under Curve , Carbamates/chemistry , Carbamates/pharmacokinetics , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacokinetics , Male , Rats , Rats, Wistar
7.
Nat Neurosci ; 13(10): 1265-70, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20852626

ABSTRACT

Peripheral cannabinoid receptors exert a powerful inhibitory control over pain initiation, but the endocannabinoid signal that normally engages this intrinsic analgesic mechanism is unknown. To address this question, we developed a peripherally restricted inhibitor (URB937) of fatty acid amide hydrolase (FAAH), the enzyme responsible for the degradation of the endocannabinoid anandamide. URB937 suppressed FAAH activity and increased anandamide levels outside the rodent CNS. Despite its inability to access brain and spinal cord, URB937 attenuated behavioral responses indicative of persistent pain in rodent models of peripheral nerve injury and inflammation and prevented noxious stimulus-evoked neuronal activation in spinal cord regions implicated in nociceptive processing. CB1 cannabinoid receptor blockade prevented these effects. These results suggest that anandamide-mediated signaling at peripheral CB1 receptors controls the access of pain-related inputs to the CNS. Brain-impenetrant FAAH inhibitors, which strengthen this gating mechanism, might offer a new approach to pain therapy.


Subject(s)
Arachidonic Acids/metabolism , Arachidonic Acids/therapeutic use , Cannabinoid Receptor Modulators/metabolism , Cannabinoid Receptor Modulators/therapeutic use , Endocannabinoids , Pain/prevention & control , Polyunsaturated Alkamides/metabolism , Polyunsaturated Alkamides/therapeutic use , Amidohydrolases/deficiency , Amidohydrolases/metabolism , Animals , Cannabinoid Receptor Modulators/antagonists & inhibitors , Cannabinoids/pharmacology , Cannabinoids/therapeutic use , Carrageenan , Chromatography, Liquid/methods , Disease Models, Animal , Drug Administration Routes , Drug Administration Schedule , Enzyme Inhibitors , Escape Reaction/drug effects , Ethylene Glycols/metabolism , Feeding Behavior/drug effects , Formaldehyde , Gene Expression Regulation/drug effects , Gene Expression Regulation/genetics , Hyperalgesia/drug therapy , Hyperalgesia/genetics , Indoles/therapeutic use , Male , Mass Spectrometry/methods , Mice , Mice, Inbred C57BL , Mice, Knockout , Monoacylglycerol Lipases/metabolism , Motor Activity/drug effects , Oncogene Proteins v-fos/metabolism , PPAR alpha/deficiency , Pain/chemically induced , Pain/genetics , Pain/pathology , Pain Measurement/drug effects , Pain Threshold/drug effects , Peripheral Nervous System Diseases , Piperidines/therapeutic use , Pyrazoles/therapeutic use , Rats , Rats, Sprague-Dawley , Rimonabant , Sciatica/drug therapy , Spinal Cord/metabolism , Statistics, Nonparametric , Time Factors , Tissue Distribution/drug effects , Tritium
8.
Pharmacol Res ; 61(5): 419-29, 2010 May.
Article in English | MEDLINE | ID: mdl-20044005

ABSTRACT

Bilateral olfactory bulbectomy (OBX) in rodents produces behavioral and neurochemical changes associated clinically with depression and schizophrenia. Most notably, OBX induces hyperlocomotion in response to the stress of exposure to a novel environment. We examined the role of the endocannabinoid system in regulating this locomotor response in OBX and sham-operated rats. In our study, OBX-induced hyperactivity was restricted to the first 3 min of the open field test, demonstrating the presence of novelty (0-3 min) and habituation (3-30 min) phases of the open field locomotor response. Levels of the endocannabinoids 2-arachidonoylglycerol (2-AG) and anandamide were decreased in the ventral striatum, a brain region deafferented by OBX, whereas cannabinoid receptor densities were unaltered. In sham-operated rats, 2-AG levels in the ventral striatum were negatively correlated with distance traveled during the novelty phase. Thus, low levels of 2-AG are reflected in a hyperactive open field response. This correlation was not observed in OBX rats. Conversely, 2-AG levels in endocannabinoid-compromised OBX rats correlated with distance traveled during the habituation phase. In OBX rats, pharmacological blockade of cannabinoid CB(1) receptors with either AM251 (1 mg kg(-1) i.p.) or rimonabant (1 mg kg(-1) i.p.) increased distance traveled during the habituation phase. Thus, blockade of endocannabinoid signaling impairs habituation of the hyperlocomotor response in OBX, but not sham-operated, rats. By contrast, in sham-operated rats, effects of CB(1) antagonism were restricted to the novelty phase. These findings suggest that dysregulation in the endocannabinoid system, and 2-AG in particular, is implicated in the hyperactive locomotor response induced by OBX. Our studies suggest that drugs that enhance 2-AG signaling, such as 2-AG degradation inhibitors, might be useful in human brain disorders modeled by OBX.


Subject(s)
Arachidonic Acids/physiology , Cannabinoid Receptor Modulators/physiology , Endocannabinoids , Glycerides/physiology , Motor Activity/physiology , Olfactory Bulb/physiology , Signal Transduction/physiology , Animals , Autoradiography , Chromatography, High Pressure Liquid , Cyclohexanols , Densitometry , Dopamine/physiology , Environment , Limbic System/physiology , Lipid Metabolism/physiology , Male , Mass Spectrometry , Piperidines/pharmacology , Pyrazoles/pharmacology , Radiopharmaceuticals , Rats , Rats, Sprague-Dawley , Receptor, Cannabinoid, CB1/physiology , Rimonabant
9.
ChemMedChem ; 4(9): 1505-13, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19637155

ABSTRACT

The fatty acid ethanolamides are a class of signaling lipids that include agonists at cannabinoid and alpha type peroxisome proliferator-activated receptors (PPARalpha). In the brain, these compounds are primarily hydrolyzed by the intracellular serine enzyme fatty acid amide hydrolase (FAAH). O-aryl carbamate FAAH inhibitors such as URB597 are being evaluated clinically for the treatment of pain and anxiety, but interactions with carboxylesterases in liver might limit their usefulness. Here we explore two strategies aimed at overcoming this limitation. Lipophilic N-terminal substitutions, which enhance FAAH recognition, yield potent inhibitors but render such compounds susceptible to attack by broad-spectrum hydrolases and inactive in vivo. By contrast, polar electron-donating O-aryl substituents, which decrease carbamate reactivity, yield compounds, such as URB694, that are highly potent FAAH inhibitors in vivo and less reactive with off-target carboxylesterases. The results suggest that an approach balancing inhibitor reactivity with target recognition produces FAAH inhibitors that display significantly improved drug-likeness.


Subject(s)
Amidohydrolases/antagonists & inhibitors , Carbamates/chemistry , Enzyme Inhibitors/chemistry , Amidohydrolases/metabolism , Animals , Biphenyl Compounds/chemistry , Biphenyl Compounds/pharmacokinetics , Carbamates/pharmacokinetics , Carbamates/pharmacology , Carboxylesterase/metabolism , Enzyme Inhibitors/pharmacology , Half-Life , Male , Rats , Rats, Wistar , Structure-Activity Relationship
10.
ChemMedChem ; 4(9): 1495-504, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19554599

ABSTRACT

Cyclohexylcarbamic acid aryl esters are a class of fatty acid amide hydrolase (FAAH) inhibitors, which includes the reference compound URB597. The reactivity of their carbamate fragment is involved in pharmacological activity and may affect their pharmacokinetic and toxicological properties. We conducted in vitro stability experiments in chemical and biological environments to investigate the structure-stability relationships in this class of compounds. The results show that electrophilicity of the carbamate influences chemical stability, as suggested by the relation between the rate constant of alkaline hydrolysis (log k(pH9)) and the energy of the lowest unoccupied molecular orbital (LUMO). Introduction of small electron-donor substituents at conjugated positions of the O-aryl moiety increased the overall hydrolytic stability of the carbamate group without affecting FAAH inhibitory potency, whereas peripheral non-conjugated hydrophilic groups, which favor FAAH recognition, helped decrease oxidative metabolism in the liver.


Subject(s)
Amidohydrolases/antagonists & inhibitors , Carbamates/chemistry , Enzyme Inhibitors/chemistry , Amidohydrolases/metabolism , Animals , Carbamates/pharmacology , Drug Stability , Enzyme Inhibitors/pharmacology , Half-Life , Male , Rats , Rats, Wistar , Structure-Activity Relationship
11.
Neuropharmacology ; 56 Suppl 1: 235-43, 2009.
Article in English | MEDLINE | ID: mdl-18691603

ABSTRACT

The endocannabinoid system modulates neurotransmission at inhibitory and excitatory synapses in brain regions relevant to the regulation of pain, emotion, motivation, and cognition. This signaling system is engaged by the active component of cannabis, Delta9-tetrahydrocannabinol (Delta9-THC), which exerts its pharmacological effects by activation of G protein-coupled type-1 (CB1) and type-2 (CB2) cannabinoid receptors. During frequent cannabis use a series of poorly understood neuroplastic changes occur, which lead to the development of dependence. Abstinence in cannabinoid-dependent individuals elicits withdrawal symptoms that promote relapse into drug use, suggesting that pharmacological strategies aimed at alleviating cannabis withdrawal might prevent relapse and reduce dependence. Cannabinoid replacement therapy and CB1 receptor antagonism are two potential treatments for cannabis dependence that are currently under investigation. However, abuse liability and adverse side-effects may limit the scope of each of these approaches. A potential alternative stems from the recognition that (i) frequent cannabis use may cause an adaptive down-regulation of brain endocannabinoid signaling, and (ii) that genetic traits that favor hyperactivity of the endocannabinoid system in humans may decrease susceptibility to cannabis dependence. These findings suggest in turn that pharmacological agents that elevate brain levels of the endocannabinoid neurotransmitters, anandamide and 2-arachidonoylglycerol (2-AG), might alleviate cannabis withdrawal and dependence. One such agent, the fatty-acid amide hydrolase (FAAH) inhibitor URB597, selectively increases anandamide levels in the brain of rodents and primates. Preclinical studies show that URB597 produces analgesic, anxiolytic-like and antidepressant-like effects in rodents, which are not accompanied by overt signs of abuse liability. In this article, we review evidence suggesting that (i) cannabis influences brain endocannabinoid signaling and (ii) FAAH inhibitors such as URB597 might offer a possible therapeutic avenue for the treatment of cannabis withdrawal.


Subject(s)
Cannabinoid Receptor Modulators/physiology , Cannabinoid Receptor Modulators/therapeutic use , Endocannabinoids , Marijuana Abuse/drug therapy , Animals , Arachidonic Acids/antagonists & inhibitors , Arachidonic Acids/pharmacology , Arachidonic Acids/therapeutic use , Humans , Polyunsaturated Alkamides/antagonists & inhibitors , Polyunsaturated Alkamides/pharmacology , Polyunsaturated Alkamides/therapeutic use , Receptor, Cannabinoid, CB1/physiology
12.
Biol Psychiatry ; 64(11): 930-7, 2008 Dec 01.
Article in English | MEDLINE | ID: mdl-18814866

ABSTRACT

BACKGROUND: CB(1) cannabinoid receptors in the brain are known to participate in the regulation of reward-based behaviors. However, the contribution of each of the endocannabinoid transmitters, anandamide and 2-arachidonoylglycerol (2-AG), to these behaviors remains undefined. To address this question, we assessed the effects of URB597, a selective anandamide deactivation inhibitor, as a reinforcer of drug-seeking and drug-taking behavior in squirrel monkeys. METHODS: We investigated the reinforcing effects of the fatty acid amide hydrolase (FAAH) inhibitor URB597 in monkeys trained to intravenously self-administer Delta(9)-tetrahydrocannabinol (THC), anandamide, or cocaine and quantified brain endocannabinoid levels using liquid chromatography/mass spectrometry. We measured brain FAAH activity using an ex vivo enzyme assay. RESULTS: URB597 (.3 mg/kg, intravenous) blocked FAAH activity and increased anandamide levels throughout the monkey brain. This effect was accompanied by a marked compensatory decrease in 2-AG levels. Monkeys did not self-administer URB597, and the drug did not promote reinstatement of extinguished drug-seeking behavior previously maintained by THC, anandamide, or cocaine. Pretreatment with URB597 did not modify self-administration of THC or cocaine, even though, as expected, it significantly potentiated anandamide self-administration. CONCLUSIONS: In the monkey brain, the FAAH inhibitor URB597 increases anandamide levels while causing a compensatory down-regulation in 2-AG levels. These effects are accompanied by a striking lack of reinforcing properties, which distinguishes URB597 from direct-acting cannabinoid agonists such as THC. Our results reveal an unexpected functional heterogeneity within the endocannabinoid signaling system and suggest that FAAH inhibitors might be used therapeutically without risk of abuse or triggering of relapse to drug abuse.


Subject(s)
Amidohydrolases/metabolism , Arachidonic Acids/administration & dosage , Brain/drug effects , Brain/enzymology , Dronabinol/administration & dosage , Polyunsaturated Alkamides/administration & dosage , Reinforcement, Psychology , Analysis of Variance , Animals , Behavior, Animal/drug effects , Benzamides/pharmacology , Brain/anatomy & histology , Cannabinoid Receptor Modulators/metabolism , Carbamates/pharmacology , Chromatography, Liquid/methods , Cocaine/administration & dosage , Dose-Response Relationship, Drug , Endocannabinoids , Male , Rats , Rats, Wistar , Reinforcement Schedule , Saimiri , Self Administration/methods
13.
J Med Chem ; 51(12): 3487-98, 2008 Jun 26.
Article in English | MEDLINE | ID: mdl-18507372

ABSTRACT

Alkylcarbamic acid biphenyl-3-yl esters are a class of fatty acid amide hydrolase (FAAH) inhibitors that comprises cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597), a compound with analgesic, anxiolytic-like and antidepressant-like properties in rat and mouse models. Here, we extended the structure-activity relationships (SARs) for this class of compounds by replacing the cyclohexyl ring of the parent compound cyclohexylcarbamic acid biphenyl-3-yl ester (URB524) (FAAH IC50 = 63 nM) with a selected set of substituents of different size, shape, flexibility, and lipophilicity. Docking experiments and linear interaction energy (LIE) calculations indicated that the N-terminal group of O-arylcarbamates fits within the lipophilic region of the substrate-binding site, mimicking the arachidonoyl chain of anandamide. Significant potency improvements were observed for the beta-naphthylmethyl derivative 4q (IC50 = 5.3 nM) and its 3'-carbamoylbiphenyl-3-yl ester 4z (URB880, IC50 = 0.63 nM), indicating that shape complementarity and hydrogen bonds are crucial to obtain highly potent inhibitors.


Subject(s)
Amidohydrolases/antagonists & inhibitors , Amidohydrolases/chemistry , Biphenyl Compounds/chemical synthesis , Carbamates/chemical synthesis , Quantitative Structure-Activity Relationship , Biphenyl Compounds/chemistry , Carbamates/chemistry , Hydrogen Bonding , Models, Molecular
14.
Chem Biol ; 14(12): 1357-65, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18096504

ABSTRACT

The N-aryl carbamate URB602 (biphenyl-3-ylcarbamic acid cyclohexyl ester) is an inhibitor of monoacylglycerol lipase (MGL), a serine hydrolase involved in the biological deactivation of the endocannabinoid 2-arachidonoyl-sn-glycerol (2-AG). Here, we investigated the mechanism by which URB602 inhibits purified recombinant rat MGL by using a combination of biochemical and structure-activity relationship (SAR) approaches. We found that URB602 weakly inhibits recombinant MGL (IC(50) = 223 +/- 63 microM) through a rapid and noncompetitive mechanism. Dialysis experiments and SAR analyses suggest that URB602 acts through a partially reversible mechanism rather than by irreversible carbamoylation of MGL. Finally, URB602 (100 microM) elevates 2-AG levels in hippocampal slice cultures without affecting levels of other endocannabinoid-related substances. Thus, URB602 may provide a useful tool by which to investigate the physiological roles of 2-AG and explore the potential interest of MGL as a therapeutic target.


Subject(s)
Arachidonic Acids/metabolism , Biphenyl Compounds/pharmacology , Brain/drug effects , Glycerides/metabolism , Monoacylglycerol Lipases/antagonists & inhibitors , Amides , Animals , Arachidonic Acids/chemistry , Arachidonic Acids/pharmacology , Biphenyl Compounds/chemistry , Brain/metabolism , Catalysis/drug effects , Cerebellum/drug effects , Cerebellum/metabolism , Endocannabinoids , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Ethanolamines , HeLa Cells , Hippocampus/drug effects , Hippocampus/metabolism , Humans , Kinetics , Male , Monoacylglycerol Lipases/genetics , Monoacylglycerol Lipases/metabolism , Organophosphonates/chemistry , Organophosphonates/pharmacology , Palmitic Acids/metabolism , Polyunsaturated Alkamides/metabolism , Rats , Rats, Wistar , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Structure-Activity Relationship , Transfection
15.
Ann Chim ; 97(9): 887-94, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17970304

ABSTRACT

The compound URB754 was recently identified as a potent inhibitor of the endocannabinoid-deactivating enzyme monoacylglycerol lipase (MGL) by screening of a commercial chemical library. Based on HPLC/MS, NMR and EI/MS analyses, the present paper shows that the MGL-inhibitory activity attributed to URB754 is in fact due to a chemical impurity present in the commercial sample, identified as bis(methylthio)mercurane. Although this organomercurial compound is highly potent at inhibiting MGL (IC50 = 11.9 +/- 1.1 nM), its biological use is prohibited by its toxicity and target promiscuity.


Subject(s)
Aniline Compounds/analysis , Benzoxazines/analysis , Chromatography, High Pressure Liquid , Magnetic Resonance Spectroscopy , Spectrometry, Mass, Electrospray Ionization
16.
Pharmacol Res ; 54(5): 341-4, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16935521

ABSTRACT

The O-arylcarbamate URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester; also referred to as KDS-4103) is a potent inhibitor of fatty-acid amide hydrolase (FAAH), an intracellular serine hydrolase responsible for the inactivation of the endogenous cannabinoid anandamide. URB597 demonstrates a remarkable degree of selectivity for FAAH over other serine hydrolases (e.g. cholinesterases) or other components of the endocannabinoid system (e.g. cannabinoid receptors). However, in a proteomic-based selectivity screen based on the displacement of fluorophosphonate-rhodamine (FPR) from mouse brain proteins, it was recently shown that URB597 prevents FPR binding to triacylglycerol hydrolase (TGH) with a median inhibitory concentration of 192nM. To determine whether this effect correlates with inhibition of TGH activity, we investigated the ability of URB597 to inhibit triolein hydrolysis in rat liver and heart tissues, which are rich in TGH, as well as white adipose tissue (WAT), which is rich in adipose triacylglycerol lipase (TGL) and hormone-sensitive lipase. The results show that URB597 does not affect triolein hydrolysis in any of these tissues at concentrations as high as 10microM, whereas it inhibits FAAH activity at low nanomolar concentrations. Moreover, intraperitoneal (i.p.) administration of URB597 at doses that maximally inhibit FAAH in vivo (0.3-3mgkg(-1)) exerts no effect on triolein hydrolysis and tissue triacylglycerol (TAG) levels in rat liver, heart or WAT. The results indicate that URB597, while potent at inhibiting FAAH, does not affect TGH and TGL activities in rat tissues.


Subject(s)
Amidohydrolases/antagonists & inhibitors , Benzamides/pharmacology , Carbamates/pharmacology , Enzyme Inhibitors/pharmacology , Triglycerides/metabolism , Triolein/metabolism , Adipose Tissue, White/drug effects , Adipose Tissue, White/metabolism , Amidohydrolases/metabolism , Animals , Brain/drug effects , Brain/metabolism , Hydrolysis/drug effects , Liver/drug effects , Liver/metabolism , Male , Myocardium/metabolism , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...